Publications by authors named "Ashley Spahn"
Article Synopsis
- Hematopoietic cell transplantation (HCT) has seen significant advancements over time, influenced by research data from the Center for International Blood and Marrow Transplant Research (CIBMTR).
- The CIBMTR Biorepository maintains a diverse inventory of biospecimens, which can be utilized for further analyses to enhance understanding and practices in HCT.
- Ongoing collaboration and utilization of these resources are aimed at improving patient outcomes and expanding research opportunities in the field of HCT.
Background: The optimal timing of vaccination with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines after cellular therapy is incompletely understood. The objectives of this study are to determine whether humoral and cellular responses after SARS-CoV-2 vaccination differ if initiated <4 months versus 4-12 months after cellular therapy.
Methods: We conducted a multicenter, prospective, observational study at 30 cancer centers in the United States.
Background: The optimal timing of vaccination with SARS-CoV-2 vaccines after cellular therapy is incompletely understood.
Objective: To describe humoral and cellular responses after SARS-CoV-2 vaccination initiated <4 months versus 4-12 months after cellular therapy.
Design: Multicenter prospective observational study.
Background: The optimal timing for SARS-CoV-2 vaccines within the first year after allogeneic hematopoietic cell transplant (HCT) is poorly understood.
Methods: We conducted a prospective, multicentre, observational study of allogeneic HCT recipients who initiated SARS-CoV-2 vaccinations within 12 months of HCT. Participants were enrolled at 22 academic cancer centers across the United States.
Article Synopsis
- Natural killer (NK) cell effectiveness increases when their inhibitory receptors (KIR) can't interact with HLA class I molecules, leading to enhanced targeting and killing of cancer cells.
- Research on hematopoietic cell transplants (HCT) from 1988 to 2009 revealed that donors with KIR B haplotypes led to better outcomes for acute myeloid leukemia (AML) patients due to lower relapse rates, especially in cases with significant HLA mismatch.
- In a more recent study (2010-2016), KIR B haplotype donors were found to significantly lower relapse risk and improve survival for AML patients undergoing reduced intensity conditioning (RIC) HCT, particularly for those
KIR Donor Selection: Feasibility in Identifying better Donors.
Biol Blood Marrow Transplant
January 2019
We previously reported that acute myelogenous leukemia (AML) transplants using killer cell immunoglobulin-type receptor (KIR) B haplotype better or best (≥2 B activating gene loci ± Cen B/B) unrelated donors (URDs) yield less relapse and better survival. In this prospective trial we evaluated 535 AML searches from 14 participating centers with centralized donor KIR genotyping for donor selection. This represented 3% to 48% of all AML searches (median 20%) per center, totaling 3 to 172 patients (median 22) per center.
View Article and Find Full Text PDFBackground: The choroid plexus (CP) is an epithelial and vascular structure in the ventricular system of the brain that is a critical part of the blood-brain barrier. The CP has two primary functions, 1) to produce and regulate components of the cerebral spinal fluid, and 2) to inhibit entry into the brain of exogenous substances. Despite its importance in neurobiology, little is known about how this structure forms.
View Article and Find Full Text PDF